Price
No data yet.
Social Signal Score
Analyst Ratings
22 analystsRevenue
$632.63M+197.09%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Parth Mehrotra
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Employees
- 1,226
- Beta
- 0.80
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 0.18
Financials
Revenue
$632.63M+197.1%Net Income
$9.05M+67.1%EBITDA
$20.11M+194.2%Free Cash Flow
$-177.05MEPS (diluted)
$0.07+32.8%Shares Outstanding (diluted)
131.83M+28.3%Operating Expenses
$47.66MCash & Debt
$412.20BRevenue by Segment (annual)
$2.12BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.12B | $22.92M | $0.19 |
| 2024 | $1.74B | $14.38M | $0.12 |
| 2023 | $1.66B | $23.08M | $0.20 |
| 2022 | $1.36B | $-8.59M | $-0.08 |
| 2021 | $966.22M | $-188.23M | $-1.77 |
| 2020 | $817.08M | $31.24M | $0.30 |
| 2019 | $786.36M | $8.24M | $0.08 |
| 2018 | $657.61M | $-3.04M | $-0.03 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.28
- Implied price
- $4.96
- Return from $20.25
- -24.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $2.47 — -87.8% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | -36.8% | -34.0% | -31.5% | -29.4% | -27.5% |
| 3.0% | -33.6% | -30.6% | -28.0% | -25.8% | -23.8% |
| 8.0% | -30.4% | -27.2% | -24.5% | -22.2% | -20.1% |
| 13.0% | -27.2% | -23.9% | -21.0% | -18.6% | -16.4% |
| 18.0% | -24.0% | -20.5% | -17.5% | -15.0% | -12.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·6h ago·Neutral
Privia Health to Report Third Quarter 2026 Results on Thursday, November 5 ARLINGTON, Va., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its third-quarter and nine-month periods ended September 30, 2026 before market open on Thursday, November 5, 2026.
View source ↗ - Newsbusinesswire.com·3d ago·Neutral
Anthem Blue Cross and Blue Shield in Virginia and Privia Health Reach New Agreement RICHMOND, Va.--(BUSINESS WIRE)--Anthem Blue Cross and Blue Shield in Virginia and Privia Health have reached a new agreement that will continue providing Anthem members with in-network access to Privia Medical Group physicians across Virginia.The agreement reflects a shared commitment to ensuring Virginians have access to high-quality healthcare while advancing value-based care and helping keep healthcare afforda
View source ↗ - Newsglobenewswire.com·51d ago·Neutral
Privia Health Announces Appointment of Opella Ernest, M.D. to its Board of Directors ARLINGTON, Va., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced the appointment of Opella Ernest, M.D.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $0.09 per share
Typical surprise -40.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$0.07 vs $0.07beat
- Thu, May 7$0.02 vs $0.08miss
- Thu, Feb 26$0.07 vs $0.04beat
- Thu, Nov 6$0.05 vs $0.06miss
- Thu, Aug 7$0.02 vs $0.05miss
- Thu, May 8$0.03 vs $0.06miss
Estimates and results for PRVA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PRVA officers and directors.
- Bought
- —
- Sold
- $20.0m
0 trades
39 trades
- Mountcastle Davidsold
- Mountcastle Davidsold
- Morris Matthew Shawnsold
- Morris Matthew Shawnsold
- Mountcastle Davidsold
- Morris Matthew Shawnsold
- Morris Matthew Shawnsold
- Morris Matthew Shawnsold
61 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PRVA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.